Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGC Canopy Growth	$1.19 -4.0%	$1.42	$0.77 ▼ $8.65	$227.99M	0.75	6.15 million shs	9.74 million shs
DBVT DBV Technologies	$8.56 -8.9%	$9.16	$2.20 ▼ $12.78	$257.46M	-0.63	190,516 shs	38,581 shs
DTIL Precision BioSciences	$4.53 -5.4%	$5.07	$3.61 ▼ $11.09	$53.11M	1.48	187,596 shs	73,209 shs
PRQR ProQR Therapeutics	$1.95 +1.0%	$1.65	$1.07 ▼ $4.62	$203.06M	0.31	644,325 shs	273,680 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGC Canopy Growth	0.00%	-16.22%	-32.24%	+6.90%	-81.90%
DBVT DBV Technologies	0.00%	+3.30%	+11.77%	+110.76%	+93.81%
DTIL Precision BioSciences	0.00%	-2.24%	+4.59%	-15.07%	-49.04%
PRQR ProQR Therapeutics	0.00%	+2.66%	+15.57%	+16.97%	+12.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGC Canopy Growth	2.4184 of 5 stars	2.5	2.0	0.0	2.6	0.0	1.3
DBVT DBV Technologies	2.9195 of 5 stars	3.3	5.0	0.0	1.1	2.5	0.6
DTIL Precision BioSciences	4.1625 of 5 stars	3.5	3.0	4.6	0.6	1.7	1.3
PRQR ProQR Therapeutics	1.2661 of 5 stars	3.6	3.0	0.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGC Canopy Growth	1.00	Sell	$2.00	68.07% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	72.31% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	937.53% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	310.26% Upside

Current Analyst Ratings Breakdown

Latest DTIL, CGC, DBVT, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/28/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGC Canopy Growth	$225.65M	0.97	N/A	N/A	$1.90 per share	0.63
DBVT DBV Technologies	$4.15M	56.50	N/A	N/A	$1.42 per share	6.03
DTIL Precision BioSciences	$68.70M	0.73	N/A	N/A	$6.87 per share	0.66
PRQR ProQR Therapeutics	$20.46M	10.03	N/A	N/A	$0.91 per share	2.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGC Canopy Growth	-$429.86M	-$4.04	N/A	N/A	N/A	-195.76%	-88.54%	-40.78%	8/8/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)

Latest DTIL, CGC, DBVT, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGC Canopy Growth	0.62	3.12	2.10
DBVT DBV Technologies	N/A	0.72	0.72
DTIL Precision BioSciences	0.45	6.62	6.62
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGC Canopy Growth	3.33%
DBVT DBV Technologies	71.74%
DTIL Precision BioSciences	37.99%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
CGC Canopy Growth	1.30%
DBVT DBV Technologies	1.44%
DTIL Precision BioSciences	4.00%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGC Canopy Growth	3,150	183.87 million	181.48 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
DTIL Precision BioSciences	200	11.09 million	10.64 million	No Data
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

DTIL, CGC, DBVT, and PRQR Headlines

Recent News About These Companies

Cantor Fitzgerald Comments on PRQR FY2026 Earnings

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)

June 6, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 3, 2025 | tipranks.com

ProQR Therapeutics (NASDAQ:PRQR) Short Interest Up 50.9% in May

June 2, 2025 | marketbeat.com

Northern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)

May 30, 2025 | marketbeat.com

Millennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR)

May 28, 2025 | marketbeat.com

Woodline Partners LP Buys Shares of 3,557,001 ProQR Therapeutics (NASDAQ:PRQR)

May 25, 2025 | marketbeat.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

ProQR: Q1 Earnings Snapshot

May 10, 2025 | finance.yahoo.com

ProQR Announces First Quarter 2025 Operating and Financial Results

May 8, 2025 | globenewswire.com

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 2, 2025 | globenewswire.com

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

May 1, 2025 | globenewswire.com

ProQR Therapeutics initiated with an Outperform at Evercore ISI

April 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, CGC, DBVT, and PRQR Company Descriptions

Canopy Growth NASDAQ:CGC

$1.19 -0.05 (-4.03%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 +0.02 (+1.68%)

As of 07:53 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

DBV Technologies NASDAQ:DBVT

$8.56 -0.84 (-8.94%)

Closing price 03:57 PM Eastern

Extended Trading

$9.51 +0.95 (+11.05%)

As of 04:21 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Precision BioSciences NASDAQ:DTIL

$4.53 -0.26 (-5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$4.68 +0.15 (+3.20%)

As of 07:54 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

ProQR Therapeutics NASDAQ:PRQR

$1.95 +0.02 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$1.95 0.00 (0.00%)

As of 07:54 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time